Molecular insights into cancer drug resistance from a proteomics perspective

  title={Molecular insights into cancer drug resistance from a proteomics perspective},
  author={Yao An and Li Zhou and Zhao Huang and Edouard C Nice and Haiyuan Zhang and Canhua Huang},
  journal={Expert Review of Proteomics},
  pages={413 - 429}
ABSTRACT Introduction: Resistance to chemotherapy and development of specific and effective molecular targeted therapies are major obstacles facing current cancer treatment. Comparative proteomic approaches have been employed for the discovery of putative biomarkers associated with cancer drug resistance and have yielded a number of candidate proteins, showing great promise for both novel drug target identification and personalized medicine for the treatment of drug-resistant cancer. Areas… Expand
5 Citations
SILAC-Based Quantitative Proteomics Identifies Multifactorial Mechanism of Oxaliplatin Resistance in Pancreatic Cancer Cells
In this study, a stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomic analysis of oxaliplatin-resistant and sensitive pancreatic cancer PANC-1 cells is performed and reveals that MARCKS and WLS might be involved in the chemotherapeutic resistance in Pancic cancer. Expand
Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications
The recent progress in overcoming cancer drug resistance is summarized in three novel aspects: mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation, and posttranslational modification on molecules, which encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis. Expand
SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells
Analysis of stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomics analysis of oxaliplatin-resistant and sensitive pancreatic cancer PANC-1 cells reveals that MARCKS and WLS might be involved in the oxali platin resistance. Expand
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
This work reviewed recent studies related to the effects of ULK1 on the regulation of autophagy and the development of drug resistance in cancers, with the aim of clarifying the mechanistic underpinnings of this therapeutic target. Expand
Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology.
An overview of the experimental workflows commonly used in DIA-MS, including its current strengths and limitations versus conventional data-dependent acquisition mass spectrometry (DDA-MS), and a number of key studies to illustrate the power of this technology when applied to different facets of oncology are summarized. Expand


Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
The recent advancements on proteomic investigation of chemoresistance in human cancer are reviewed, and putative biomarkers for predicting chemotherapeutic response and possible mechanisms of Chemoresistance identified through proteomic approaches are reviewed. Expand
Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification
This review will present recent advances in proteogenomic investigations of cancer drug resistance with an emphasis on integrative proteogenomics pipelines and the biomarker discovery which contributes to achieving the goal of using precision/personalized medicine for cancer treatment. Expand
Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives
The current advantages and limitations ofclinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical Proteomics-driven precision medicine for targeted cancer therapy are discussed. Expand
Cancer Metabolism and Drug Resistance
Some of the major findings associated with the metabolic pathways in cancer cells are discussed and new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs are discussed. Expand
Quantitative Proteomics Analysis Identifies Mitochondria as Therapeutic Targets of Multidrug-Resistance in Ovarian Cancer
Stable isotope labeling by amino acids in cell culture (SILAC)-based quantitative proteomic strategy was applied to compare mitochondrial protein expression in doxorubicin sensitive OVCAR8 cells and its doxorbicin-resistant variant NCI_ADR/RES cells, indicating that mitochondria could be therapeutic targets ofDoxorUBicin resistance in ovarian cancer cells. Expand
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib
Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinicallyExpand
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Interestingly, the early identification of some mechanisms of resistance led to the use of alternative agents that improved clinical benefit, demonstrating that an understanding of the molecular mechanisms driving resistance to specific therapies is of paramount importance. Expand
Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
The aim of the work is to identify the proteomic profile that can be associated to the response to the PMX treatment in pre-treatement tissue and is ready for further validation in retrospective clinical trials using a targeted proteomic approach. Expand
Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
A multidimensional proteomic analysis of a cisplatin-resistant BC model that provides different levels of protein information, including that of the global proteome and phosphoproteome is introduced to provide a novel way of classifying higher-risk patients and may guide future research in developing therapeutic targets. Expand
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
The results suggest that both AGR2 and MIC-1 play a role in Docetaxel resistance in HRPC, and an increase in serum/plasmaMIC-1 level after cycle one of Docetxel may be an indication to abandon further treatment. Expand